AB0022 AUTOREACTIVE B CELLS IN RHEUMATOID ARTHRITIS DISPLAY AN ACTIVATED PHENOTYPE OF RECENT ANTIGEN EXPOSURE
Authors: N. Blomberg, H. Kristyanto, T. Huizinga, R. Toes, H. U. Scherer
Journal: Annals of the Rheumatic Diseases (2021)

Background: Rheumatoid arthritis, in particular ACPA+ RA, is characterized by frequent disease flares and poor chances to achieve DMARD-free sustained remission. Recently, we have shown that ACPA-expressing memory B cells (MBC) remain in a persistently activated state throughout disease, even in patients in DMARD-induced clinical remission.(1) The reasons why the ACPA B cell response is continuously activated are unknown, as well as why the response does not revert to a resting, ‘quiescent’ state. We hypothesized that continuous antigen exposure in germinal centres drives ACPA B cell activation, leading to a ‘recent germinal centre emigrant’ phenotype of these cells in the circulation. Objectives: To understand whether the activated phenotype of ACPA-expressing B cells could be induced by recent antigen exposure, to thereby discern the processes of immune activation that remain active in patients even in clinical remission and to argue whether these processes could be targets for therapeutic intervention. Methods: ACPA-expressing B cells were identified in peripheral blood of RA patients by flow cytometry during different stages of disease and characterized by a panel of activation- and germinal centre related markers (CD80, CD86, CD32, CD95, Ki-67). In addition, three healthy donors received a TT booster vaccination. TT-specific MBC were identified in blood at different timepoints (before vaccination and up to 22 weeks after vaccination) and analysed phenotypically over time. Results: The majority of ACPA-expressing B cells strongly expressed CD95 and the co-stimulatory marker CD80. A part was also positive for the proliferation marker Ki-67 (on average 30%), and most cells downregulated the inhibitory marker CD32. TT-specific MBC adopted a comparable phenotype after booster vaccination, but most markers returned to the pre-vaccination expression level gradually over time. These effects were antigen-dependent because the phenotype of TT-negative B cells remained unchanged. The phenotypic composition of the proliferating ACPA-positive B cell pool most closely corresponded to a stimulation history of 1-2 weeks after antigen exposure. Notably, none of the Ki-67 negative ACPA-specific MBC showed phenotypic quiescence, indicating either a short life-time (in circulation) after antigen encounter or persistent additional factors of activation. Figure 1. Ki-67 expression on ACPA-specific MBC in RA (A) and on TT-specific MBC in 3 healthy donors before and after booster vaccination (B). Conclusion: ACPA-expressing MBC phenotypically resemble TT-specific MBC after recent (1-2 weeks) booster vaccination, reflecting the phenotype of recent germinal centre emigrants, and remain activated, whereas TT-specific MBC lose this marker profile over time. These observations suggest that ACPA-expressing MBC either home to tissue or survive shortly in the circulation, or that additional factors drive or program these cells to persistent activation. Transcriptomic profiling and analysis of the homing marker profile may help to answer these questions. Furthermore, it will be important to understand the association of persistent activation of ACPA-expressing B cells in clinical remission and the risk for disease flares upon treatment discontinuation. References: [1]Kristyanto H, Blomberg NJ, Slot LM, van der Voort EIH, Kerkman PF, Bakker A, et al. Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis. Sci Transl Med. 2020;12(570). Disclosure of Interests: Nienke Blomberg: None declared, Hendy Kristyanto: None declared, Thomas Huizinga Grant/research support from: Gilead, Rene Toes: None declared, Hans Ulrich Scherer Grant/research support from: Pfizer, Lilly, Sanofi, BMS